Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

JYNT vs USPH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
JYNT
The Joint Corp.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$124M
5Y Perf.-42.6%
USPH
U.S. Physical Therapy, Inc.

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$897M
5Y Perf.-20.4%

JYNT vs USPH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
JYNT logoJYNT
USPH logoUSPH
IndustryMedical - Care FacilitiesMedical - Care Facilities
Market Cap$124M$897M
Revenue (TTM)$57M$695M
Net Income (TTM)$3M$11M
Gross Margin78.5%22.0%
Operating Margin1.1%12.2%
Forward P/E44.9x20.6x
Total Debt$2M$426M
Cash & Equiv.$24M$36M

JYNT vs USPHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

JYNT
USPH
StockMay 20May 26Return
The Joint Corp. (JYNT)10057.4-42.6%
U.S. Physical Thera… (USPH)10079.6-20.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: JYNT vs USPH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: USPH leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. The Joint Corp. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
JYNT
The Joint Corp.
The Long-Run Compounder

JYNT is the clearest fit if your priority is long-term compounding and sleep-well-at-night.

  • 191.9% 10Y total return vs USPH's 22.6%
  • Lower volatility, beta 0.98, Low D/E 13.3%, current ratio 1.59x
  • 5.7% margin vs USPH's 1.5%
Best for: long-term compounding and sleep-well-at-night
USPH
U.S. Physical Therapy, Inc.
The Income Pick

USPH carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 5 yrs, beta 0.93, yield 3.1%
  • Rev growth 16.3%, EPS growth -22.8%, 3Y rev CAGR 12.2%
  • Beta 0.93, yield 3.1%, current ratio 1.01x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthUSPH logoUSPH16.3% revenue growth vs JYNT's 5.2%
ValueUSPH logoUSPHLower P/E (20.6x vs 44.9x)
Quality / MarginsJYNT logoJYNT5.7% margin vs USPH's 1.5%
Stability / SafetyUSPH logoUSPHBeta 0.93 vs JYNT's 0.98
DividendsUSPH logoUSPH3.1% yield; 5-year raise streak; the other pay no meaningful dividend
Momentum (1Y)JYNT logoJYNT-12.8% vs USPH's -14.3%
Efficiency (ROA)JYNT logoJYNT5.0% ROA vs USPH's 0.9%

JYNT vs USPH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

JYNTThe Joint Corp.
FY 2025
Royalty
60.5%$33M
Advertising
19.0%$10M
Technology Service
11.0%$6M
Franchise
6.1%$3M
Product and Service, Other
3.3%$2M
USPHU.S. Physical Therapy, Inc.
FY 2025
Net Patient Revenues
83.3%$650M
Other Revenues Including Management Contract Revenues and Industrial Injury Prevention Services Revenues
16.7%$131M

JYNT vs USPH — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJYNTLAGGINGUSPH

Income & Cash Flow (Last 12 Months)

JYNT leads this category, winning 4 of 6 comparable metrics.

USPH is the larger business by revenue, generating $695M annually — 12.3x JYNT's $57M. Profitability is closely matched — net margins range from 5.7% (JYNT) to 1.5% (USPH). On growth, JYNT holds the edge at +13.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricJYNT logoJYNTThe Joint Corp.USPH logoUSPHU.S. Physical The…
RevenueTrailing 12 months$57M$695M
EBITDAEarnings before interest/tax$2M$107M
Net IncomeAfter-tax profit$3M$11M
Free Cash FlowCash after capex$3M$67M
Gross MarginGross profit ÷ Revenue+78.5%+22.0%
Operating MarginEBIT ÷ Revenue+1.1%+12.2%
Net MarginNet income ÷ Revenue+5.7%+1.5%
FCF MarginFCF ÷ Revenue+4.7%+9.6%
Rev. Growth (YoY)Latest quarter vs prior year+13.3%+7.7%
EPS Growth (YoY)Latest quarter vs prior year+71.4%-115.0%
JYNT leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

USPH leads this category, winning 6 of 6 comparable metrics.

At 41.5x trailing earnings, USPH trades at a 9% valuation discount to JYNT's 45.6x P/E. On an enterprise value basis, USPH's 12.5x EV/EBITDA is more attractive than JYNT's 126.9x.

MetricJYNT logoJYNTThe Joint Corp.USPH logoUSPHU.S. Physical The…
Market CapShares × price$124M$897M
Enterprise ValueMkt cap + debt − cash$103M$1.3B
Trailing P/EPrice ÷ TTM EPS45.63x41.55x
Forward P/EPrice ÷ next-FY EPS est.44.85x20.63x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple126.93x12.52x
Price / SalesMarket cap ÷ Revenue2.26x1.15x
Price / BookPrice ÷ Book value/share8.70x1.16x
Price / FCFMarket cap ÷ FCF370.99x14.71x
USPH leads this category, winning 6 of 6 comparable metrics.

Profitability & Efficiency

JYNT leads this category, winning 6 of 7 comparable metrics.

JYNT delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $1 for USPH. JYNT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to USPH's 0.55x. On the Piotroski fundamental quality scale (0–9), JYNT scores 6/9 vs USPH's 5/9, reflecting solid financial health.

MetricJYNT logoJYNTThe Joint Corp.USPH logoUSPHU.S. Physical The…
ROE (TTM)Return on equity+16.9%+1.4%
ROA (TTM)Return on assets+5.0%+0.9%
ROICReturn on invested capital+5.6%
ROCEReturn on capital employed-2.9%+7.6%
Piotroski ScoreFundamental quality 0–965
Debt / EquityFinancial leverage0.13x0.55x
Net DebtTotal debt minus cash-$22M$390M
Cash & Equiv.Liquid assets$24M$36M
Total DebtShort + long-term debt$2M$426M
Interest CoverageEBIT ÷ Interest expense15.42x
JYNT leads this category, winning 6 of 7 comparable metrics.

Total Returns (Dividends Reinvested)

JYNT leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in USPH five years ago would be worth $5,664 today (with dividends reinvested), compared to $1,608 for JYNT. Over the past 12 months, JYNT leads with a -12.8% total return vs USPH's -14.3%. The 3-year compound annual growth rate (CAGR) favors JYNT at -16.1% vs USPH's -17.4% — a key indicator of consistent wealth creation.

MetricJYNT logoJYNTThe Joint Corp.USPH logoUSPHU.S. Physical The…
YTD ReturnYear-to-date-2.0%-24.6%
1-Year ReturnPast 12 months-12.8%-14.3%
3-Year ReturnCumulative with dividends-41.0%-43.7%
5-Year ReturnCumulative with dividends-83.9%-43.4%
10-Year ReturnCumulative with dividends+191.9%+22.6%
CAGR (3Y)Annualised 3-year return-16.1%-17.4%
JYNT leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — JYNT and USPH each lead in 1 of 2 comparable metrics.

USPH is the less volatile stock with a 0.93 beta — it tends to amplify market swings less than JYNT's 0.98 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.

MetricJYNT logoJYNTThe Joint Corp.USPH logoUSPHU.S. Physical The…
Beta (5Y)Sensitivity to S&P 5000.98x0.93x
52-Week HighHighest price in past year$13.47$93.50
52-Week LowLowest price in past year$7.50$58.55
% of 52W HighCurrent price vs 52-week peak+64.4%+63.1%
RSI (14)Momentum oscillator 0–10049.346.1
Avg Volume (50D)Average daily shares traded57K171K
Evenly matched — JYNT and USPH each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates JYNT as "Buy" and USPH as "Buy". Consensus price targets imply 130.7% upside for JYNT (target: $20) vs 72.9% for USPH (target: $102). USPH is the only dividend payer here at 3.06% yield — a key consideration for income-focused portfolios.

MetricJYNT logoJYNTThe Joint Corp.USPH logoUSPHU.S. Physical The…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$20.00$102.00
# AnalystsCovering analysts812
Dividend YieldAnnual dividend ÷ price+3.1%
Dividend StreakConsecutive years of raises5
Dividend / ShareAnnual DPS$1.80
Buyback YieldShare repurchases ÷ mkt cap+9.1%+0.6%
Insufficient data to determine a leader in this category.
Key Takeaway

JYNT leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). USPH leads in 1 (Valuation Metrics). 1 tied.

Best OverallThe Joint Corp. (JYNT)Leads 3 of 6 categories
Loading custom metrics...

JYNT vs USPH: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is JYNT or USPH a better buy right now?

For growth investors, U.

S. Physical Therapy, Inc. (USPH) is the stronger pick with 16. 3% revenue growth year-over-year, versus 5. 2% for The Joint Corp. (JYNT). U. S. Physical Therapy, Inc. (USPH) offers the better valuation at 41. 5x trailing P/E (20. 6x forward), making it the more compelling value choice. Analysts rate The Joint Corp. (JYNT) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — JYNT or USPH?

On trailing P/E, U.

S. Physical Therapy, Inc. (USPH) is the cheapest at 41. 5x versus The Joint Corp. at 45. 6x. On forward P/E, U. S. Physical Therapy, Inc. is actually cheaper at 20. 6x.

03

Which is the better long-term investment — JYNT or USPH?

Over the past 5 years, U.

S. Physical Therapy, Inc. (USPH) delivered a total return of -43. 4%, compared to -83. 9% for The Joint Corp. (JYNT). Over 10 years, the gap is even starker: JYNT returned +191. 9% versus USPH's +22. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — JYNT or USPH?

By beta (market sensitivity over 5 years), U.

S. Physical Therapy, Inc. (USPH) is the lower-risk stock at 0. 93β versus The Joint Corp. 's 0. 98β — meaning JYNT is approximately 6% more volatile than USPH relative to the S&P 500. On balance sheet safety, The Joint Corp. (JYNT) carries a lower debt/equity ratio of 13% versus 55% for U. S. Physical Therapy, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — JYNT or USPH?

By revenue growth (latest reported year), U.

S. Physical Therapy, Inc. (USPH) is pulling ahead at 16. 3% versus 5. 2% for The Joint Corp. (JYNT). On earnings-per-share growth, the picture is similar: The Joint Corp. grew EPS 133. 9% year-over-year, compared to -22. 8% for U. S. Physical Therapy, Inc.. Over a 3-year CAGR, USPH leads at 12. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — JYNT or USPH?

The Joint Corp.

(JYNT) is the more profitable company, earning 5. 3% net margin versus 1. 9% for U. S. Physical Therapy, Inc. — meaning it keeps 5. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: USPH leads at 10. 3% versus -1. 6% for JYNT. At the gross margin level — before operating expenses — JYNT leads at 76. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is JYNT or USPH more undervalued right now?

On forward earnings alone, U.

S. Physical Therapy, Inc. (USPH) trades at 20. 6x forward P/E versus 44. 9x for The Joint Corp. — 24. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JYNT: 130. 7% to $20. 00.

08

Which pays a better dividend — JYNT or USPH?

In this comparison, USPH (3.

1% yield) pays a dividend. JYNT does not pay a meaningful dividend and should not be held primarily for income.

09

Is JYNT or USPH better for a retirement portfolio?

For long-horizon retirement investors, U.

S. Physical Therapy, Inc. (USPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93), 3. 1% yield). Both have compounded well over 10 years (USPH: +22. 6%, JYNT: +191. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between JYNT and USPH?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: JYNT is a small-cap quality compounder stock; USPH is a small-cap high-growth stock. USPH pays a dividend while JYNT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

JYNT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Net Margin > 5%
Run This Screen
Stocks Like

USPH

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 13%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform JYNT and USPH on the metrics below

Revenue Growth>
%
(JYNT: 13.3% · USPH: 7.7%)
P/E Ratio<
x
(JYNT: 45.6x · USPH: 41.5x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.